ArticleFrontiers in endocrinology2022
Induction of Collagen I by CXCL10 in Ovarian Theca-Stroma Cells
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Non-reproductive tumor progression impairs ovarian function through CXCL10-IL18R1 axis.Experimental & molecular medicine · 2026Article
- Bone-related adverse events of hormonal therapy: A pharmacovigilance study based on the Food & Drug Administration Adverse Event Reporting System.The Journal of international medical research · 2026Article
- DNMT/TET Imbalance and Network-Level DNA Methylation Remodeling in Ovarian Aging: Mechanistic Perspectives.Biology · 2026Review
- Ginseng and its active compounds in ovarian aging: mechanistic basis and translational prospects.Frontiers in pharmacology · 2026Review
- Metformin protects against cyclophosphamide-induced ovarian fibrosis by MIF/CD74-mediated macrophage polarization.Journal of translational medicine · 2025Article
- Ovarian remodeling and aging-related chronic inflammation and fibrosis in the mammalian ovary.Journal of ovarian research · 2025Article
- Mast cell tryptase-PAR2 axis promotes ovarian fibrosis through RNF152-mediated stabilization of Bcl-xL.Journal of ovarian research · 2025Article
- Genetic Association and Drug Target Exploration Between Inflammation-Related Proteins and the Risk of Primary Ovarian Insufficiency.Journal of inflammation research · 2025Article
- Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion.Reproductive biology and endocrinology : RB&E · 2024Article
- Redox Balance and Inflammatory Response in Follicular Fluids of Women Recovered by SARS-CoV-2 Infection or Anti-COVID-19 Vaccinated: A Combined Metabolomics and Biochemical Study.International journal of molecular sciences · 2024Article
- New Gene Markers of Exosomal Regulation Are Involved in Porcine Granulosa Cell Adhesion, Migration, and Proliferation.International journal of molecular sciences · 2023Article
- CXCL10-based gene cluster model serves as a potential diagnostic biomarker for premature ovarian failure.PeerJ · 2023Article
- Single-cell RNA sequencing of peripheral blood reveals immune cell dysfunction in premature ovarian insufficiency.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature ovarian insufficiency (POI) poses a great threat to reproductive-age women. Ovarian fibrogenesis is a basic histologic feature of POI. Ovarian theca-stroma cells are responsible for ovarian fibrosis, but few studies have focused on the ovarian microenvironment. The role and mechanism of chemokines in the development of POI remain unclear. Here, we evaluated C-X-C motif chemokine ligand 10 (CXCL10) in biochemical POI patients, POI patients, and a POI mouse model. CXCL10 levels in serum and follicular fluid were higher in both bPOI and POI patients than in controls. An increased level of CXCL10 was also observed in a POI mouse model. CXCL10 concentrations in serum and follicular fluid were positively associated with follicle-stimulating hormone and negatively associated with antral follicle count. Our study for the first time found that CXCL10 induced COL1A1 and COL1A2 production, two subunits of collagen I in mouse theca-stroma cells by activating the JNK/c-Jun pathway. Inhibition of JNK and c-Jun attenuated the increases of COL1A1 and COL1A2 caused by CXCL10. Moreover, CXCL10 had no effects on hormone synthesis, proliferation, and apoptosis in human luteinized granulosa (hGL) cells. Our findings revealed a potential diagnostic value of CXCL10 in the early stage of POI and shed new insights into the biological function of CXCL10 in ovarian fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.